EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access · CC BY-NC-ND 4.0

Phase III, multicenter, randomized trial of 45 Gy versus 30 Gy thoracic radiation for extensive‐stage small cell lung cancer ( ES‐SCLC ): Study protocol

Lei Deng iD, Gulidanna Shayan iD, Wei Jiang, Nan Bi, Luhua Wang iD

Thoracic Cancer · 2024

DOI: 10.1111/1759-7714.15263 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Thoracic Cancer, 2024. Verfasst von Lei Deng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sci…. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Consolidative thoracic radiotherapy (cTRT) has previously shown benefit to patients with extensive stage small cell lung cancer (ES‐SCLC) who respond to chemotherapy. However, the optimum dose of cTRT is unknown. The purpose of this randomized trial is to compare the efficacy of 45 Gy in 15 fractions with 30 Gy in 10 fractions cTRT in ES‐SCLC.

Methods

This phase III, multicenter, randomized trial is designed to evaluate the safety and efficacy of different cTRT dose in ES‐SCLC. Eligible patients with pathologically confirmed ES‐SCLC who responded to 4–6 cycles of etoposide plus cisplatin (EP) or carboplatin (EC) chemotherapy were randomized 1:1 to receive either 30 Gy in 10 fractions (standard dose) or 45 Gy in 15 fractions (high dose) cTRT. The primary endpoint is 2‐year overall survival (OS). Secondary endpoints include 2‐year progression‐free survival (PFS), 2‐year local control (LC) and treatment related toxicity as measured by adverse events according to the Common Terminology Criteria for Adverse Events (version 4.0).

Discussion

The present study is the first randomized phase III trial designed to evaluate the efficacy of higher versus lower dose cTRT in ES‐SCLC, providing evidence for future clinical practice in prolonging survival of patients with ES‐SCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaLung NeoplasmsHumansCisplatinAntineoplastic Combined Chemotherapy ProtocolsCarboplatinProgression-Free SurvivalRadiation DosageEtoposideRandomized Controlled Trials as TopicMulticenter Studies as TopicClinical Trials, Phase III as Topic

Stichwörter der Autor:innen

extensive stage small cell lung cancer (ES‐SCLC)radiation dosethoracic radiation

Substanzen

CisplatinCarboplatinEtoposide

Autor:innen und Institutionen

  • Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
  • Department of Radiation Oncology, National Cancer Center/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

ORCID-Profile: Lei Deng, Gulidanna Shayan, Luhua Wang

Zitieren

APA

Deng, L., Shayan, G., Jiang, W., Bi, N., & Wang, L. (2024). Phase III, multicenter, randomized trial of 45 Gy versus 30 Gy thoracic radiation for extensive‐stage small cell lung cancer ( ES‐SCLC ): Study protocol. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15263

Vancouver

Deng L, Shayan G, Jiang W, Bi N, Wang L. Phase III, multicenter, randomized trial of 45 Gy versus 30 Gy thoracic radiation for extensive‐stage small cell lung cancer ( ES‐SCLC ): Study protocol. Thoracic Cancer. 2024. doi:10.1111/1759-7714.15263

BibTeX
@article{Deng2024,
  author = {Deng, Lei and Shayan, Gulidanna and Jiang, Wei and Bi, Nan and Wang, Luhua},
  title = {Phase III, multicenter, randomized trial of 45 Gy versus 30 Gy thoracic radiation for extensive‐stage small cell lung cancer ( ES‐SCLC ): Study protocol},
  journal = {Thoracic Cancer},
  year = {2024},
  doi = {10.1111/1759-7714.15263}
}
Kostenlos starten →